Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 5.905 USD 1.03% Market Closed
Market Cap: 287.8m USD
Have any thoughts about
Uniqure NV?
Write Note

Intrinsic Value

QURE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one QURE stock under the Base Case scenario is 11.953 USD. Compared to the current market price of 5.905 USD, Uniqure NV is Undervalued by 51%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

QURE Intrinsic Value
11.953 USD
Undervaluation 51%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Uniqure NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for QURE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about QURE?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Uniqure NV

Provide an overview of the primary business activities
of Uniqure NV.

What unique competitive advantages
does Uniqure NV hold over its rivals?

What risks and challenges
does Uniqure NV face in the near future?

Has there been any significant insider trading activity
in Uniqure NV recently?

Summarize the latest earnings call
of Uniqure NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Uniqure NV.

Provide P/S
for Uniqure NV.

Provide P/E
for Uniqure NV.

Provide P/OCF
for Uniqure NV.

Provide P/FCFE
for Uniqure NV.

Provide P/B
for Uniqure NV.

Provide EV/S
for Uniqure NV.

Provide EV/GP
for Uniqure NV.

Provide EV/EBITDA
for Uniqure NV.

Provide EV/EBIT
for Uniqure NV.

Provide EV/OCF
for Uniqure NV.

Provide EV/FCFF
for Uniqure NV.

Provide EV/IC
for Uniqure NV.

Show me price targets
for Uniqure NV made by professional analysts.

What are the Revenue projections
for Uniqure NV?

How accurate were the past Revenue estimates
for Uniqure NV?

What are the Net Income projections
for Uniqure NV?

How accurate were the past Net Income estimates
for Uniqure NV?

What are the EPS projections
for Uniqure NV?

How accurate were the past EPS estimates
for Uniqure NV?

What are the EBIT projections
for Uniqure NV?

How accurate were the past EBIT estimates
for Uniqure NV?

Compare the revenue forecasts
for Uniqure NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Uniqure NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Uniqure NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Uniqure NV compared to its peers.

Compare the P/E ratios
of Uniqure NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Uniqure NV with its peers.

Analyze the financial leverage
of Uniqure NV compared to its main competitors.

Show all profitability ratios
for Uniqure NV.

Provide ROE
for Uniqure NV.

Provide ROA
for Uniqure NV.

Provide ROIC
for Uniqure NV.

Provide ROCE
for Uniqure NV.

Provide Gross Margin
for Uniqure NV.

Provide Operating Margin
for Uniqure NV.

Provide Net Margin
for Uniqure NV.

Provide FCF Margin
for Uniqure NV.

Show all solvency ratios
for Uniqure NV.

Provide D/E Ratio
for Uniqure NV.

Provide D/A Ratio
for Uniqure NV.

Provide Interest Coverage Ratio
for Uniqure NV.

Provide Altman Z-Score Ratio
for Uniqure NV.

Provide Quick Ratio
for Uniqure NV.

Provide Current Ratio
for Uniqure NV.

Provide Cash Ratio
for Uniqure NV.

What is the historical Revenue growth
over the last 5 years for Uniqure NV?

What is the historical Net Income growth
over the last 5 years for Uniqure NV?

What is the current Free Cash Flow
of Uniqure NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Uniqure NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Uniqure NV

Current Assets 464.1m
Cash & Short-Term Investments 435.2m
Receivables 5.3m
Other Current Assets 23.6m
Non-Current Assets 181.7m
Long-Term Investments 28.3m
PP&E 40.4m
Intangibles 100.7m
Other Non-Current Assets 12.3m
Current Liabilities 71.3m
Accounts Payable 5.4m
Accrued Liabilities 34.2m
Other Current Liabilities 31.7m
Non-Current Liabilities 518.7m
Long-Term Debt 477.8m
Other Non-Current Liabilities 40.9m
Efficiency

Earnings Waterfall
Uniqure NV

Revenue
28.6m USD
Cost of Revenue
-26.5m USD
Gross Profit
2m USD
Operating Expenses
-196.8m USD
Operating Income
-194.7m USD
Other Expenses
-44.8m USD
Net Income
-239.5m USD

Free Cash Flow Analysis
Uniqure NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

QURE Profitability Score
Profitability Due Diligence

Uniqure NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Negative 1-Year Revenue Growth
Declining ROE
16/100
Profitability
Score

Uniqure NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

QURE Solvency Score
Solvency Due Diligence

Uniqure NV's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Positive Net Debt
Long-Term Solvency
High D/E
30/100
Solvency
Score

Uniqure NV's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

QURE Price Targets Summary
Uniqure NV

Wall Street analysts forecast QURE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for QURE is 19.38 USD with a low forecast of 7.07 USD and a high forecast of 29.4 USD.

Lowest
Price Target
7.07 USD
20% Upside
Average
Price Target
19.38 USD
228% Upside
Highest
Price Target
29.4 USD
398% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for QURE?

Click here to dive deeper.

Dividends

Uniqure NV
does not pay dividends
Shareholder Yield

Current shareholder yield for QURE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

QURE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

QURE News

Other Videos

Profile

Uniqure NV Logo
Uniqure NV

Country

Netherlands

Industry

Biotechnology

Market Cap

287.8m USD

Dividend Yield

0%

Description

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Contact

NOORD-HOLLAND
Amsterdam
Paasheuvelweg 25a
+31202406000.0
www.uniqure.com

IPO

2014-02-05

Employees

463

Officers

CEO & Executive Director
Mr. Matthew Craig Kapusta
CFO, Principal Financial Officer & GM of Amsterdam Site
Mr. Christian Klemt
Chief Business & Scientific Officer
Mr. Richard Porter Ph.D.
Chief Legal & Compliance Officer and Corporate Secretary
Dr. Jeannette Potts J.D., Ph.D.
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Prof. Hugo Katus
Chief Technical Operations
Dr. Amin Abujoub Ph.D.
Show More
Business Development Director
Dr. Tamara Tugal Ph.D., MBA
Chief People & Culture Officer
Ms. Erin Boyer
Chief Corporate Affairs Officer
Ms. Maria E. Cantor
Chief Medical Officer
Dr. Walid Abi-Saab M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one QURE stock?

The intrinsic value of one QURE stock under the Base Case scenario is 11.953 USD.

Is QURE stock undervalued or overvalued?

Compared to the current market price of 5.905 USD, Uniqure NV is Undervalued by 51%.

Back to Top